QURE
uniQure N.V.
Key Financials
Operating Income
$-185349000
↓ 0.6%
Net Income
$-198971000
↑ 16.9%
Revenue
$3.6M
N/A
Total Assets
$824.9M
↑ 48.2%
Total Liabilities
$626.0M
↑ 11.1%
Shareholders' Equity
$198.9M
↑ 3045.8%
EPS (Diluted)
$-3.46
↑ 29.7%
Cash & Equivalents
$80.2M
↓ 49.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 144 | 5/8/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| SCHEDULE 13G/A | 4/30/2026 | View on SEC |
| 8-K | 4/30/2026 | View on SEC |
| ARS | 4/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | QURE |
| Company Name | uniQure N.V. |
| CIK | 1590560 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 1-339-970-7000 |